A brief report on Novo Nordisk's amycretin delivering notable weight loss, with no figures given in the material.
Recap by typeshit. Full story at Meteo.gr.
PHL17 shares findings that people on Ozempic and similar drugs are cutting alcohol spending at bars, restaurants and home.
Gaetano Santulli's team surveys approved oral options and late-stage pill candidates, arguing they could reach patients who avoid injections.
After 12 months, GLP-1 users shed 14.8% of the weight they had regained versus 8.1% for nonusers. Researchers stress the study was observational and small.
Omer Raheem says he presented his team's work on GLP-1 therapies past weight loss at the ISSM Journals Webinar 2026.
Meteo.gr reports strong weight loss results for amycretin, Novo Nordisk's next obesity candidate. Few details were given beyond the headline.
The Danish town that makes Ozempic and Wegovy is nicknamed Novo Town, a sign of how much these drugs have reshaped one place.
Loading…